This shows you the differences between two versions of the page.
home:protocol:olmesartan:kidney_disease [08.13.2019] – [Subclinical kidney infection] sallieq | home:protocol:olmesartan:kidney_disease [09.14.2022] (current) – external edit 127.0.0.1 | ||
---|---|---|---|
Line 12: | Line 12: | ||
===== High BUN is an indication of a successful immune response ===== | ===== High BUN is an indication of a successful immune response ===== | ||
- | One study found that hemodialysis patients who had high serum values of urea nitrogen (BUN) were less likely to have the acute infection, // | + | One study found that hemodialysis patients who had high serum values of urea nitrogen (BUN) were less likely to have the acute infection, // |
===== Vitamin D Receptor activation increases creatinine production ===== | ===== Vitamin D Receptor activation increases creatinine production ===== | ||
- | In a 2011 study appearing in //Kidney International//, | + | In a 2011 study appearing in //Kidney International//, |
< | < | ||
Line 25: | Line 25: | ||
</ | </ | ||
- | This //in vivo// study is significant as it confirms several key aspects of the Marshall Protocol: | + | This //in vivo// study is significant as it confirms several key aspects of the Marshall Protocol: |
* Patients with kidney disease on a treatment designed to stimulate the VDR can expect their measures of creatinine to increase. | * Patients with kidney disease on a treatment designed to stimulate the VDR can expect their measures of creatinine to increase. | ||
* The strategy of waiting-out abnormal creatinine values, rather than trying to intervene, is the most sensible approach currently available. | * The strategy of waiting-out abnormal creatinine values, rather than trying to intervene, is the most sensible approach currently available. | ||
Line 40: | Line 40: | ||
< | < | ||
- | // | + | // |
- | " | + | " |
- | ===== Benefits | + | |
+ | ===== Subclinical kidney infection ===== | ||
+ | |||
+ | Subclinical - that is to say, undetected or undetectable - kidney disease is common in patients with [[home: | ||
+ | |||
+ | Once patients activate the [[home: | ||
+ | ===== Olmesartan benefits | ||
According to a 2008 commentary appearing in //Nature//: | According to a 2008 commentary appearing in //Nature//: | ||
Line 49: | Line 55: | ||
< | < | ||
- | // | + | // |
MP patients with kidney inflammation and their healthcare practitioners should be extremely comforted by the fact that the patient is taking olmesartan. This is due to the great number of studies, which have found that olmesartan and other ARBs protect the kidneys from the effects of inflammation and cytokine damage. | MP patients with kidney inflammation and their healthcare practitioners should be extremely comforted by the fact that the patient is taking olmesartan. This is due to the great number of studies, which have found that olmesartan and other ARBs protect the kidneys from the effects of inflammation and cytokine damage. | ||
Line 55: | Line 61: | ||
The benefits of olmesartan on patients with kidney inflammation include | The benefits of olmesartan on patients with kidney inflammation include | ||
- | * decreased insulin resistance, fewer symptoms of the metabolic syndrome, and decreased inflammation in patients with chronic kidney disease.(({{pubmed> | + | * decreased insulin resistance, fewer symptoms of the metabolic syndrome, and decreased inflammation in patients with chronic kidney disease.(({{pmid> |
- | * decreased (intra)renal vascular resistance, increased renal perfusion, and significantly reduced oxidative stress in patients with type 2 diabetes(({{pubmed> | + | * decreased (intra)renal vascular resistance, increased renal perfusion, and significantly reduced oxidative stress in patients with type 2 diabetes(({{pmid> |
- | * protection of the kidneys in diabetic nephropathy | + | * protection of the kidneys in diabetic nephropathy |
- | * offer a survival benefit in hemodialysis patients, may help in preservation of renal function in predialysis patient, and affect the tissue repair process, reducing renal fibrosis(({{pubmed> | + | * offer a survival benefit in hemodialysis patients, may help in preservation of renal function in predialysis patient, and affect the tissue repair process, reducing renal fibrosis(({{pmid> |
- | * prevention of the onset of microalbuminuria in patients with Type 2 diabetes(({{pubmed> | + | * prevention of the onset of microalbuminuria in patients with Type 2 diabetes(({{pmid> |
Line 66: | Line 72: | ||
< | < | ||
- | // | + | // |
The effects of ARBs, in general, on people with kidney inflammation include: | The effects of ARBs, in general, on people with kidney inflammation include: | ||
- | * improved patient prognosis in non-diabetic chronic kidney diseases with mild-to-moderate renal dysfunction.(({{pubmed> | + | * improved patient prognosis in non-diabetic chronic kidney diseases with mild-to-moderate renal dysfunction.(({{pmid> |
* effectiveness in controlling UAE [urinary albumin excretion] in cases in which blood pressure is not well controlled, implying that ARBs have renoprotective actions independent of changes in blood pressure. | * effectiveness in controlling UAE [urinary albumin excretion] in cases in which blood pressure is not well controlled, implying that ARBs have renoprotective actions independent of changes in blood pressure. | ||
- | * ability to actively control proteinuria and stabilize kidney function in children, providing an alternative to more toxic therapies, especially corticosteroids, | + | * ability to actively control proteinuria and stabilize kidney function in children, providing an alternative to more toxic therapies, especially corticosteroids, |
- | * formation of a dosage-dependent, | + | * formation of a dosage-dependent, |
- | * ability to retard the progression of advanced renal insufficiency.(({{pubmed> | + | * ability to retard the progression of advanced renal insufficiency.(({{pmid> |
- | * effective slowing of the progression of chronic allograft nephropathy (CAN)(({{pubmed> | + | * effective slowing of the progression of chronic allograft nephropathy (CAN)(({{pmid> |
Line 86: | Line 92: | ||
==== Animal studies ==== | ==== Animal studies ==== | ||
- | [[http:// | + | [[https:// |
- | Ability to affect the local renin-angiontensin sytem (RAS) and thus improve renal injury and function in a rat model of potentially progressive glomerulosclerosis.(({{pubmed> | + | Ability to affect the local renin-angiontensin sytem (RAS) and thus improve renal injury and function in a rat model of potentially progressive glomerulosclerosis.(({{pmid> |
- | Ability of Olmesartan to ameliorate renal injury and fibrosis in rats when taken at ultrahigh doses.(({{pubmed> | + | Ability of Olmesartan to ameliorate renal injury and fibrosis in rats when taken at ultrahigh doses.(({{pmid> |
{{tag> | {{tag> | ||
+ | < | ||
===== Notes and comments ===== | ===== Notes and comments ===== | ||
Line 106: | Line 113: | ||
" | " | ||
- | http:// | + | https:// |
Line 127: | Line 134: | ||
- | ===== References====== | + | ===== References======</ |